Imfinzi (durvalumab) Approved in the US for Extensive-Stage Small Cell Lung Cancer

30 March 2020 -- AstraZeneca’s Imfinzi (durvalumab) has been approved in the US as a 1st-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) in combination with standard-of-care (SoC)...

Source: Drugs.com - New Drug Approvals - March 30, 2020 Category: Drugs & Pharmacology Source Type: news